MultiCell Technologies Inc. (OTC:MCET) is working on a stent that combines two drugs aimed at reducing restenosis ’ salicylate, aspirin’s active ingredient, and sirolimus. This polymer stent will be designed to dissolve completely over the course of a year.
A coronary stent is a tube placed in the coronary arteries that supply the heart, to keep the arteries open in the treatment of coronary heart disease.
One of the drawbacks of vascular stents is the potential for restenosis via the development of a thick smooth muscle tissue inside the lumen, the so-called neointima. Development of a neointima is variable but can at times be so severe as to re-occlude the vessel lumen (restenosis), especially in the case of smaller diameter vessels, which often results in reintervention. Consequently, current research focuses on the reduction of neointima after stent placement. Considerable improvements have been made, including the use of more bio-compatible materials, anti-inflammatory drug-eluting stents, resorbable stents, and others. Restenosis can be treated with a reintervention using the same method.
Recently, Abbott Laboratories received CE Mark approval in the European Union for its Absorb bioresorbable vascular stent for treating blocked coronary arteries. The device, like other stents, works by opening up and providing support to clogged arteries. Unlike its metal counterparts, however, the device is designed to dissolve within approximately two years after implantation there by reducing Restenosis.
MultiCell Technologies, Inc. engages in the research, discovery, development, and commercialization of therapeutics using its proprietary cell-based systems and immune system modulation technologies. It involves in the research and development targeting degenerative neurological diseases, including multiple sclerosis and cancer. They are currently working on
- MCT-125, a Phase IIb clinical trial therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue.
- MCT-465, a preclinical adjuvant therapeutic candidate for the treatment of TLR3+ cancers.
- MCT-475, a preclinical therapeutic candidate for the treatment of TLR3+ breast cancer.
- Research and development of Sybiol technology( synthetic bio-liver therapeutic liver assist device).